Tesamorelin Research: A GHRH Analog and the GH/IGF-1 Axis

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It works upstream: it prompts the pituitary to release the body's own growth hormone in a pulsatile pattern. Tesamorelin is an FDA-approved drug. It was approved in 2010 under the brand name Egrifta to reduce excess abdominal fat in HIV-associated lipodystrophy, so its literature includes formal randomized trials in humans. That approval covers the licensed medicine only; it does not extend to research-grade material, which is supplied for laboratory research use only. The summary below reports what published studies found and doesn't describe any use of research material.

Working upstream of growth hormone

Instead of supplying growth hormone directly, a GHRH analog signals the pituitary to release it, which keeps the natural pulsatile rhythm of the GH/IGF-1 axis. Reviews describe tesamorelin in exactly these terms, as a GHRH analog (Spooner & Olin, Ann Pharmacother, 2012).

The lipodystrophy trials

Tesamorelin's clinical record centers on visceral adipose tissue in HIV-associated lipodystrophy. Randomized trials reported reductions in visceral adipose tissue compared with placebo (Falutz et al., J Clin Endocrinol Metab, 2010). That trial record is the basis for its approval, and it's why the compound comes up in metabolic research.

Research at the tissue level

More recent studies have looked at tesamorelin's effects in specific tissues, including hepatic transcriptomic signatures in research on HIV-associated fatty liver (Fourman et al., JCI Insight, 2020).

Note: the approved drug Egrifta is a prescription medicine for a specific clinical population. Research-grade tesamorelin is not that medicine and is for laboratory research use only, not for human or veterinary use, diagnosis or treatment.

FAQ

How is a GHRH analog different from growth hormone itself?

It acts further up the chain. It signals the pituitary to release the body's own growth hormone in its natural pulsatile rhythm, rather than providing growth hormone directly.

Is there human data on tesamorelin?

Yes. It was tested in randomized clinical trials in HIV-associated lipodystrophy and approved by the FDA in 2010 as Egrifta. That approval applies to the licensed drug and does not change the research-use-only status of research-grade material.

Related guides

• Ipamorelin research, a related GH secretagogue

References

1. Spooner & Olin — tesamorelin GHRF analog review (Ann Pharmacother, 2012)
2. Falutz et al. — tesamorelin & visceral fat in HIV lipodystrophy (JCEM, 2010)
3. Fourman et al. — tesamorelin & hepatic signatures (JCI Insight, 2020)